Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of preservative-free tafluprost + timolol fixed-dose combination versus concomitant tafluprost and timolol in open-angle glaucoma or ocular hypertension
2010-022984-36Phase 3Completed
- Sponsor
- Santen Pharmaceutical
- Start
- Dec 2010
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of tafluprost and timolol in open-angle glaucoma (OAG) and ocular hypertension (2 arms), sponsored by Santen Pharmaceutical. Primary endpoint: Change from baseline in average diurnal intraocular pressure at 6 months. Started Dec 2010; status: completed.
02
Drugs
tafluprosttimolol
03
Conditions
open-angle glaucoma (OAG)ocular hypertension
Beyond the preview
Go deeper on 2010-022984-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-022984-36.